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Abstract
During severe sepsis, microvesicles that are positive for tissue factor (TF) are at increased levels 
within blood and in pulmonary lavage. These microvesicles potentially disperse TF, the major 
initiator of the coagulation cascade, throughout multiple organ systems, initiating fibrin deposition 
and resultant ischemia. The source of these microvesicles has remained incompletely defined. 
Although TF+ microvesicles are shed from cells that express nascent TF transcript in response to 
injury, recent findings revealed that circulating, full-length TF protein is detectable prior to these 
nascent transcripts. This finding suggested that the protein is released from constitutive sources as 
an acute response. We examined whether Staphylococcus aureus, the Gram-positive bacteria that 
is emerging as one of the most common etiologic agents in sepsis, is capable of stimulating the 
release of TF+ microvesicles from a pulmonary cell line that constitutively expresses TF protein. 
We found that host cell invasion stimulated an acute release of TF+ microvesicles and that these 
microvesicles mediated the transfer of the protein to TF-negative endothelial cells. We also found 
that transfer was inhibited by cholesterol-lowering simvastatin. Taken together, our findings reveal 
that S. aureus pathogenesis extends to the acute release of TF+ microvesicles and that inhibiting 
dispersal by this mechanism may provide a therapeutic target.
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1. Introduction
From 1999 to 2005, the estimated number of sepsis-associated deaths in the US exceeded 
one million [1]. Etiology has shifted from predominantly Gram-negative to Gram-positive 
bacteria with Staphylococcus aureus emerging as one of the most commonly identified 
pathogens [2]. The severe coagulopathy that characterizes sepsis has been associated with an 
increase in TF+ microvesicles within blood [3] and within pulmonary lavage [4]. These 
microvesicles that are characteristically 1–4 µm in size are shed from cellular membranes 
continuously, yet their numbers increase in response to specific inflammatory mediators. 
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Their increased shedding potentially disseminates TF, the major initiator of coagulation, 
leading to fibrin deposition and ischemia throughout multiple organ systems [3–5].
The shedding of TF+ microvesicles in response to pathogen invasion was reported initially 
in Ebola virus infection and subsequently has been identified during infection by a subset of 
clinically important pathogens associated with severe coagulopathy [6]. The primary source 
for the initiating TF has been attributed to the stimulation of nascent transcript [4,6,7]. 
However, recent findings indicated that these inducible sources are insufficient to account 
for the total level of circulating TF protein detected acutely in response to injury [7]. More 
recently, full-length TF protein was detected in lavage prior to the detection of TF transcript 
in healthy volunteers instilled with lipoteichoic acid, a cell wall component of Gram-positive 
bacteria [8], raising the possibility that full-length protein is released prior to the induction 
of new transcript. In support of this concept, subsets of pulmonary cells are known to 
constitutively express full-length TF protein [9–12]. These findings led to the hypothesis 
that an acute source of TF+ microvesicles during infection may include constitutively 
expressed TF protein within pulmonary cells. We therefore explored whether H441 cells, a 
lung-derived cell line that we found to constitutively express TF, would generate TF+ 
microvesicles and whether the pathogenesis of S. aureus extends to the stimulation of their 
acute release.
2. Materials and methods
2.1. S. aureus infection
Bacterial cultures were pelleted (3 min, 10,000 rpm, 37 °C) and washed once in saline. For 
the majority of studies, the strain used was ATCC 29213 (American Type Culture 
Collection, Manassas, VA). This strain induces sepsis in vivo [13] and is invasive [14,15]. 
To investigate the role of invasion, minimally invasive ATCC 700699 also was examined.
2.2. TF detection
H441 cells (ATCC) were seeded at 3 × 104 into 35 mm dishes. On day 2 of plating, cells 
were infected and suspended using cell scrapers. To detect intracellular TF, surface proteins 
were fixed in FACS buffer (2% BSA/0.1% sodium azide/PBS) containing 4% para-
formaldehyde, permeabilized in 0.5% Tween-20/PBS (15 min on ice), and incubated with 
TF-PE (BD, Franklin Lakes, NJ; 30 min, on ice). To detect surface TF, cells were stained 
with TF-PE prior to fixing and were not permeabilized. The isotype control (BD) confirmed 
specificity of antibody staining.
2.3. Microvesicle isolation
H441 cells were seeded at 2 × 105 or U-87 MG cells (ATCC) at 2 × 106 into 100 mm culture 
dishes. Preliminary data had indicated higher density plating led to diminished TF 
expression in the H441 cells. Culture dishes for the U-87 MG cells were coated with 
Attachment Factor (Life Technologies, Carlsbad, CA). On day 2, supernatants were 
harvested following infection at an MOI of 300. Low speed centrifugation cleared the 
supernatant (10 min, 500×g, 4 °C). The microvesicle fraction was isolated from the cleared 
supernatant by higher speed centrifugation (30 min, 17,000×g, 4 °C). To remove bacteria 
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that may have been isolated by this centrifugation, pellets were incubated (30 min, 5% CO2, 
37 °C) with 50 µg/ml gentamicin (Life Technologies) /20 µg/ml lysostaphin (Sigma–
Aldrich). Centrifugations were repeated and the resultant pellet harvested. The nomenclature 
of shed vesicles has yet to be standardized [16,17]. Using the same centrifugation strategy, 
the resultant pellet has been termed either the microvesicle fraction [18] or the microparticle 
fraction [19,20]. For the current study, the resultant pellet is referred to as the microvesicle 
fraction. The pellet was resuspended in FACS buffer, incubated with TF-PE, fixed in FACS 
buffer containing 0.74% formaldehyde, and immediately analyzed using an Accuri C6 flow 
cytometer (BD) by gating on particles within the 1–4 µm range.
2.4. Microvesicle transfer assay
Human umbilical vein endothelial cells (HUVEC; Life Technologies) were seeded at 5 × 
104 into 35 mm culture dishes coated with Attachment Factor. The next day, cells were 
incubated with simvastatin (EMD Millipore, Germany) or with dimethyl sulfoxide (18–20 
h). Microvesicles were harvested from H441 or from U-87 MG cells infected at an MOI of 
400, resuspended in 1.2 ml PBS. Endocytosis in HUVEC was halted (10 min, 4 °C), freshly 
harvested microvesicles added (500 µl from the H441 or 100 µl from the U-87 MG cells), 
allowed to adhere (20 min, 4 °C), and endocytosis initiated (1 h, 37 °C).
2.5. Statistical analysis
Differences between groups were considered statistically significant at P ≤ 0.05 by Student’s 
t-test or one-way ANOVA followed by Student–Newman–Keuls post-hoc analysis (Sigma 
Stat, Systat, Point Richmond, CA, USA).
3. Results
3.1. Host cell invasion mobilizes TF
Previous work had shown that constitutively expressed TF protein localizes within 
intracellular pools and at the cell surface and can be mobilized for release within shed 
microvesicles [21–23]. We explored whether host cell invasion by S. aureus is capable of 
stimulating this mobilization. In response to increasing MOI, intracellular pools diminished, 
suggesting that the intracellular source of TF had been mobilized (Fig. 1, Panel A). Cell 
surface TF decreased as well (Fig. 1, Panel B), indicating that host cell invasion stimulates 
the mobilization of both intracellular and cell surface TF.
3.2. Particles within the microvesicle fractions are TF+
To evaluate whether the decrease in intracellular and cell surface TF that had been observed 
in response to infection corresponded to an accumulation of shed TF+ microvesicles, 
supernatants from uninfected and infected H441 cells were subjected to centrifugation and 
the microvesicle fractions examined by flow cytometry. U-87 MG cells, a glioblastoma-
derived cell line with well-characterized TF+ microvesicle release [24], was examined as a 
comparator. In both cell types, the microvesicle population increased in response to 
infection and microvesicles were TF+ (Fig. 2). TF+ microvesicles also were detected within 
the fraction isolated from uninfected cells, supporting the concept that the shedding of 
microvesicles from cell membranes appears to be a normal physiologic process [17] that is 
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accelerated in a variety of pathogenic states [25]. These data indicate that the host cell 
response to invasion by S. aureus includes an increased release of TF+ microvesicles. The 
release corresponds to the mobilization of TF, suggesting that in this lung-derived cell line, 
TF mobilization results in release as TF+ microvesicles.
3.3. Viable, invasive bacteria are required for TF release
To begin to explore underlying mechanisms of TF release, we examined whether active 
bacterial invasion is required or whether stimulation of endocytosis by heat-killed bacteria is 
sufficient. TF release was detectable only in response to viable, invasive bacteria, not merely 
endocytic uptake (Fig. 3, Panel A). To explore further the potential role of invasiveness, the 
response to a minimally invasive strain was examined. TF release again was detectable only 
in response to invasive ATCC 29213, not in response to minimally invasive ATCC 700699 
(Fig. 3, Panel C), further supporting the concept that active bacterial invasion is required for 
the release of TF by the host cell.
3.4. Simvastatin limits the transfer of TF from TF+ microvesicles to TF-negative endothelial 
cells
Microvesicles function as transporters, transferring biomolecules such as DNA, RNA, and 
protein, from donor to acceptor cells [17]. We therefore examined whether the TF released 
within shed microvesicles could be transferred to TF-negative acceptor cells. In response to 
incubation with the microvesicle fraction from H441 cells, intracellular TF became 
detectable within HUVEC (Fig. 4, Panel A). Transfer of microvesicles from U-87 MG cells 
was more robust (Fig. 4, Panel B). Pretreatment of HUVEC with actinomycin D, an 
inhibitor of transcription, failed to attenuate the level of TF detected in HUVEC, indicating 
that full-length TF protein had been transferred rather than TF transcription induced (data 
not shown).
Previous work had indicated that simvastatin inhibits endocytic uptake that is dependent on 
the precise localization of small-GTP-ases within cellular membranes [14,15,26,27]. 
Although incompletely understood, transfer of biomolecules to the acceptor cell relies in 
part on endocytic uptake [17]. We therefore examined whether pretreatment at the acceptor 
cell could limit the transfer of TF from shed microvesicles. The more robust TF transfer by 
U-87 MG-derived microvesicles was examined. Simvastatin pretreatment of TF-negative 
HUVEC inhibited transfer (Fig. 4, Panel C). Taken together, these findings indicate that the 
mobilization and release of TF in the form of microvesicles can lead to the transfer of TF to 
endothelial cells and that this transfer is inhibited partially by simvastatin.
4. Discussion
Until recently, the biological relevance of host cell invasion by S. aureus had been 
challenged [28]. Historically, S. aureus had been considered an extracellular pathogen, and 
invasion appeared to be an in vitro artifact. However, an emerging concept is that invasion 
by S. aureus contributes significantly to pathogenesis by stimulating pro-inflammatory 
responses, enabling the evasion of antibiotics and immune cell surveillance, and establishing 
intracellular bacterial reservoirs of chronic infection [28–34]. Our findings would suggest 
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that pathogenesis extends to the release of TF+ microvesicles. An alternative possibility is 
that the acute release of TF may provide a mechanism for walling-off infection [35]. 
Although this possibility remains to be examined directly, inhibitors of coagulation have 
been found to limit damage to pulmonary tissue rather than promote the spread of infection 
[36], suggesting that the observed acute release of TF would contribute to pathogenesis.
Controversy has surrounded the nomenclature and characterization of shed microvesicles 
[16], yet their importance in the dispersal of biomolecules at distal sites has become more 
clearly defined in a variety of pathogenic states [17]. Our findings indicate that 
microvesicles shed during infection enable the dispersal of TF to TF-negative endothelial 
cells and that simvastatin limits this mechanism of transfer. Whether inhibition of the uptake 
of TF is protective, or alternatively, whether uptake is a mechanism of clearance that 
inhibition would impair, remains to be fully clarified. In vivo, simvastatin improved survival 
and diminished procoagulant TF activity in a murine model of bacterial sepsis [37], 
suggesting that the overall effect of statin treatment would be to blunt rather than prolong 
the procoagulant state. In the current work, inhibition of uptake in vitro is modest (20%). 
However, inhibition of dispersal in vivo would be in the context of the additional pleotropic 
effects of statins, such as the inhibition of TF transcription [38], and in this context, may 
contribute to limiting pathogenesis.
Our findings indicate that constitutive sources release TF+ microvesicles in response to 
invasion by one of the most commonly identified etiologic agents of sepsis. Patient 
populations at an increased risk of death due to severe infection are characterized by a 
procoagulant status [39] that has been associated with an elevation in circulating TF+ 
microvesicles [40]. The significance of our finding is that the distribution of procoagulant 
TF appears to be an early event initiated by constitutive sources. Although therapies that 
singly target procoagulant molecules have met with limited success, our work builds upon 
previous findings that statin pharmacology could address severe infection on multiple fronts, 
including improvement in cardiovascular and immune function and suppression of TF 
transcription from inducible sources [41,42]. Taken together, these findings will contribute 
to the on-going assessment of the safety and efficacy of statin use in the treatment of severe 
infection and provide strategies for advancing new therapeutic approaches.
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Levels of intracellular and cell surface tissue factor (TF) decrease with increasing 
multiplicities of infection (MOI). H441 were incubated with Staphylococcus aureus (1 h) at 
increasing MOI, harvested, and TF detected by flow cytometric analysis. Panel A to detect 
intracellular TF, cell surface proteins were fixed prior to permeabilizing and staining with 
TF-PE. Panel B for the detection of cell surface TF, cells were stained with TF-PE prior to 
fixing and were not permeabilized. Data are representative of replicate experiments (*P ≤ 
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0.05 by one-way ANOVA followed by Student–Newman–Keuls post-hoc analysis; n = 3/
group).
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Particles within the microvesicle fraction increase in response to invasion and are positive 
for tissue factor (TF+). H441 or U-87 MG cells were incubated with Staphylococcus aureus 
(1 h). Following infection, supernatants were harvested, microvesicle fractions isolated by 
centrifugation, pellets stained with TF-PE and analyzed by flow cytometry, gating for 1–4 
µm particles. Data are representative of replicate experiments.
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Viable, invasive bacteria are required for tissue factor (TF) release from H441 cells. Panel A 
bacteria were heat-killed (80 °C, 20 min), incubated with H441 cells (1 h), and TF detected 
by flow cytometric analysis. TF release was not detectable in response to heat-killed 
bacteria. Panel B H441 cells were infected with American Type Culture Collection (ATCC) 
700699 or with ATCC 29213 (1 h), extracellular bacteria removed using the bactericides 
gentamicin and lysostaphin, permeabilized using the detergent saponin, and serial dilutions 
of the medium containing bacteria plated on tryptic soy agar for colony counts (16 h). 
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ATCC 700699 was found to be minimally invasive compared to ATCC 29213. Panel C 
H441 cells were incubated with the minimally invasive strain ATCC 700699 or with ATCC 
29213 and TF detected using flow cytometry. TF release from H441 cells was not detectable 
in response to the minimally invasive strain (*P ≤ 0.05 by one-way ANOVA followed by 
Student–Newman–Keuls post-hoc analysis, Panels A and C; or by Student’s t-test, Panel B; 
n = 3/group. Data are representative of replicate experiments).
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Simvastatin limits transfer of tissue factor (TF) from TF+ microvesicles to TF-negative 
endothelial cells. Panel A TF-negative human umbilical vein endothelial cells (HUVEC) 
were incubated with TF+ microvesicles (1 h) harvested from infected H441 or Panel B from 
infected U-87 MG. Panel C HUVEC were pretreated with simvastatin (10 µM) or with 
dimethyl sulfoxide (DMSO) as the vehicle control (18–20 h) prior to incubation (1 h) with 
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the microvesicle fraction from infected U-87 MG. Intracellular and cell surface TF was 
detected by flow cytometric analysis (*P ≤ 0.05 by Student’s t-test; n = 3/group).
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